Glenmark Pharmaceuticals Enters $29.63 Million Settlement in US Antitrust Litigation
Glenmark Pharmaceuticals Enters $29.63 Million Settlement in US Antitrust Litigation Read Post »
Covers price-sensitive disclosures including accidents, legal issues, defaults, credit rating changes, and major disruptions. These events can significantly impact stock movement.